The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -81.99%.However, over the last six months, we can see a stronger performance of -78.81%. Over the last 30 days, the price of CYCC has leaped by -39.51%. And in the last five days, it has fallen by -23.27%.
Cyclacel Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $9.69 on 11/09/23 and the lowest value was $0.38 on 11/07/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of CYCC Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cyclacel Pharmaceuticals Inc’s current trading price is -95.04% away from its 52-week high, while its distance from the 52-week low is 28.27%. The stock’s price range during this period has varied between$0.38 and $9.69. The Cyclacel Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.67 million for the day, a figure considerably higher than their average daily volume of 1.09 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cyclacel Pharmaceuticals Inc (CYCC) has experienced a quarterly decline of -64.97% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.16M.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.2166, with a change in price of -1.0190. Similarly, Cyclacel Pharmaceuticals Inc recorded 766,975 in trading volume during the last 100 days, posting a change of -67.93%.
CYCC’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CYCC stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
CYCC Stock Stochastic Average
Cyclacel Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 5.01%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 5.01%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 2.69% and 1.44%, respectively.
